European Drugmakers Delay New Medicine Launches Over Pricing Pressure
Global Health Headlines: Drugs, Vaccines, and Policies in Focus | Health
Drugmakers in Europe are holding back the introduction of new medicines due to price policy changes under pressure from the US administration This move follows President Donald Trumps efforts to tie US drug costs to prices in other countries a strategy known as most-favored-nation pricing
European pharmaceutical companies are postponing new drug introductions amid stricter price policies influenced by US administration pressure. President Trump's most-favored-nation pricing strategy, which ties US drug costs to international prices, has prompted drugmakers to reconsider their market expansion timelines. The policy shift could delay patient access to innovative treatments across Europe.
Original Article
Read full article on DevdiscourseExplore More
Related News
For Your Health — What to Know About GLP-1 Drugs for Weight Loss and Health
Wayne County Journal Banner · 2026.04.14
World Health Day 2026: Global Health at a Crossroads
Chicago Council on Global Affairs · 2026.04.13
Shrestha, health advocates push for universal health care
Daily Freeman · 2026.04.13
Health Headlines Unveiled: From Genetic Discoveries to Lucrative Deals | Health
Devdiscourse · 2026.04.12
Trump's 2027 Budget Deepens Cuts To Global And Domestic Health - Health Policy Watch
Health Policy Watch · 2026.04.12
Op-Ed: We all need public health. Public health needs you. — Waterbury Roundabout
Waterbury Roundabout · 2026.04.14